Real-Time Breath Analysis in Acute Myeloid Leukaemia for a Rapid Characterisation of Biological Subtypes and to Predict Therapy Responses (EXHALE)
Exhalomics for Phenotyping and Real-Time Stratification in Acute Myeloid Leukaemia (EXHALE)
Patients with acute myeloid leukaemia (AML) respond to treatment to differing degrees, owing to the biological diversity of the disease. The diagnostic tests currently available for identifying genetic alterations and selecting the best possible treatment usually take several days before a result is obtained. In our study, the investigators aim to determine whether breath analysis can detect metabolic products of the leukaemia that allow the disease to be classified rapidly.
Participants will undergo additional blood tests and a breath analysis during their routine appointments. This will take place only during the 1st and 2nd treatment cycles. They will also be asked to complete a questionnaire about their state of health. In addition, the study team will collect further information on their state of health (type of leukaemia, type of treatment, other medications, vital signs) from their medical records.
In total, participants will complete 4 such measurements before and during their treatment. The measurements will be coordinated with their outpatient appointments. No assessments will be carried out unless the participants are at the hospital in any case, and they will not have to attend the hospital more often because of their participation in this study.
研究概览
地位
条件
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名：Jeremy W Deuel, PD MD PhD
- 电话号码：+41 41 255 11 11
- 邮箱：haematologie-onkologie@usz.ch
研究联系人备份
- 姓名：Kevin D Hofer, MD
- 电话号码：+41 255 11 11
- 邮箱：haematologie-onkologie@usz.ch
学习地点
-
-
Canton of Zurich
-
Zurich、Canton of Zurich、瑞士、8091
- University Hospital of Zurich
-
接触：
- Jeremy W Deuel, PD MD PhD
- 电话号码：+41 41 255 11 11
- 邮箱：haematologie-onkologie@usz.ch
-
接触：
- Kevin D Hofer, MD
- 电话号码：+41 41 255 11 11
- 邮箱：haematologie-onkologie@usz.ch
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
描述
Inclusion Criteria:
- Diagnosis of an acute myeloid leukaemia and undergoing treatment
- OR undergoing autoHSCT for lymphoid/myeloma disease in remission
Exclusion Criteria:
- inability to perform brath analysis
- anatomical barriers preventing use of the mouthpiece.
学习计划
研究是如何设计的？
设计细节
队列和干预
团体/队列 |
|---|
|
AML
Patient with the Diagnosis (initial or relapsed/refractory) of AML
|
|
Negative Controls
Patients undergoing high-dose Chemotherapy with autologous stem cell support (autoHSCT) due to lymphoma or myeloma in remission
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
A breath metabolite signature representing AML disease burden
大体时间：8 weeks
|
A breath metabolite signature representing AML disease burden, and might represent novel AML subtypes or describe cancer metabolic status.
|
8 weeks
|
合作者和调查者
赞助
调查人员
- 首席研究员：Jeremy W Deuel, PD MD PhD、University of Zurich
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- HumRes68544 (注册表标识符：humanforschung-schweiz.ch)
- SNCTP000007074 (注册表标识符：SNCTP)
- BASEC2026-00409 (注册表标识符：swissethics / BASEC)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)？
IPD 计划说明
IPD 共享时间框架
IPD 共享访问标准
IPD 共享支持信息类型
- 分析代码
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.